SpectraCure AB has conducted a concept study for the development of the company's technology for the treatment of prostate cancer using photodynamic therapy (PDT).
SpectraCures current PDT system, SpectraCure P18 with IDOSE®, has evolved over a ten-year period and is currently used in a Phase 1 clinical trial for the treatment of patients with relapse of prostate cancer. Prior to product launch, this system will be updated with a modern design and improved user interface and ergonomics. This step is deemed necessary before launch, in particular to reduce the production costs of the system. Many of the components and technical solutions contained in the current system will be updated and replaced. In addition, future users expect the design and user interface to correspond to a modern medical device.
"We are very happy to see the next generation of P18 forming" says Johannes Swartling, CTO of SpectraCure. “The progress in our clinical studies is now matched with advances in the technological design. Together with further development of the software IDOSE®, this results in the next generation of SpectraCures systems being more user friendly for hospital staff and also more adaptable to the patient’s individual conditions. This will make it easier for the doctors at the clinics to use SpectraCures systems, which is an important part of the launch”.
Prototype manufacturing will start in 2018.
